Arcadia Biosciences annual meeting drew 52.3% of outstanding shares represented

• Arcadia Biosciences held its annual shareholder meeting on Sept. 10, 2026.
• Shareholders adopted the 2026 Omnibus Equity Incentive Plan, replacing the expired 2015 plan; prior awards remain governed by the earlier plan.
• Authorization was granted for potential issuance of common stock upon exercise of Series A-1 Preferred Investment Options from the June 12, 2026 private placement.
• Investors endorsed an amendment allowing the board to execute a reverse stock split before June 30, 2027, at a 1-for-2 to 1-for-10 ratio.
• Ratification passed for Ramirez Jimenez International CPAs as independent auditor for the year ending Dec. 31, 2026; meeting adjournment authority was also approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-391780), on September 15, 2026, and is solely responsible for the information contained therein.